Rübe C, Micke O, Grevers G, Rohloff R, Kaufmann H, Busch M, Willich N
Klinik und Poliklinik für Strahlentherapie-Radioonkologie, Westfälische Wilhelms-Universität Münster.
Strahlenther Onkol. 1997 Feb;173(2):83-90. doi: 10.1007/BF03038927.
In the treatment of laryngeal carcinoma definitive radiotherapy results in a similar outcome as surgical treatment in the early stages with a lower morbidity rate and good functional results. In fact no randomized studies exist, so far, and the optimal treatment concept for the different stages is not well defined. The following study analyses retrospectively the treatment results and the recurrence data in patients with a squamous cell carcinoma of the larynx treated with definitive radiotherapy.
Two hundreds and eighty-three patients with carcinoma of the larynx were treated with radiation therapy in the department of radiology of the LMU München between September 1971 and June 1986. Twenty-six patients (9.2%) were female and 257 (73.1%) male. The median age was 68.5 years, respectively 70 years. All patients had a histologically confirmed squamous cell carcinoma of the larynx. No true subglottic cases were observed. Forty-one (14.5%) tumors were localized supraglottically, 207 (73.1%) glottically. Thirty-five patients had a T4 tumor with glottic and supraglottic involvement. In 147 patients the histopathological grading was evaluable: 32 tumors were classified as G1, 95 as G2, 15 as G3 and 5 as G4. According to the UICC classification of 1979 25 patients had a carcinoma in situ (Tis), 93 patients had a stage T1, 90 stage T2, 40 stage T3 and 35 stage T4. Two hundreds and thirty-three of 283 (82.3%) had no lymph node involvement. In 50 patients clinically a lymph node involvement was observed. 22 patients had a stage N1, 5 patients stage N2 and 23 patients stage N3. An external beam radiation mostly with cobalt-60 was performed with a mean dose of 61.9 Gy.
The 5-years relapse-free survival for the whole group was 61.7%. The probability for "no evidence of disease" (NED) depended on tumor stage and localisation (glottic tumors: Tis/T1 90.5%: T2 59.4%: T3 39.6%: [5-year NED]; supraglottic tumors T1 64.2%: T2/3 28.6%: T4/N3 24.7% [3-year NED]). Other significant prognostic factors besides T-stage were N-stage (NO vs. N1-3: 3-year recurrence-free survival 68% vs. 37.2%, p < 0.001) and histopathologic grading (G1 vs. G3/4: 3-year recurrence-free survival 74% vs. 37.1%, p < 0.01). One hundred and twenty-two (43.1%) patients had a recurrence, which occurred in 75.4% local, in 12.3% loco regional, in 8.2%, with distant metastases and 4.1% combined. In 50 patients with a recurrent disease a salvage therapy was carried out. Thereby 17 patients achieved a complete response.
Even for the here described negatively selected patient group with a high median age and multimorbidity, good local control rates could be achieved especially in early stages with definitive radiation therapy. In more advanced stages even in elderly patients a combined surgical-radiotherapeutic treatment should be performed.
在喉癌治疗中,早期阶段的根治性放疗与手术治疗效果相似,且发病率较低,功能效果良好。事实上,目前尚无随机对照研究,不同阶段的最佳治疗方案尚未明确界定。以下研究回顾性分析了接受根治性放疗的喉鳞状细胞癌患者的治疗结果和复发数据。
1971年9月至1986年6月期间,慕尼黑大学医学院放射科对283例喉癌患者进行了放射治疗。其中女性26例(9.2%),男性257例(73.1%)。中位年龄分别为68.5岁和70岁。所有患者均经组织学确诊为喉鳞状细胞癌。未观察到真正的声门下病例。41例(14.5%)肿瘤位于声门上区,207例(73.1%)位于声门区。35例患者的肿瘤为T4期,累及声门和声门上区。147例患者的组织病理学分级可评估:32例肿瘤为G1级,95例为G2级,15例为G3级,5例为G4级。根据1979年国际抗癌联盟(UICC)分类,25例患者为原位癌(Tis),93例为T1期,90例为T2期,40例为T3期,35例为T4期。283例患者中有233例(82.3%)无淋巴结转移。50例患者临床观察到有淋巴结转移。22例患者为N1期,5例为N2期,23例为N3期。主要采用钴-60进行外照射,平均剂量为61.9 Gy。
全组患者的5年无复发生存率为61.7%。“无疾病证据”(NED)的概率取决于肿瘤分期和部位(声门区肿瘤:Tis/T1期为90.5%,T2期为59.4%,T3期为39.6%[5年NED];声门上区肿瘤T1期为64.2%,T2/T3期为28.6%,T4/N3期为24.7%[3年NED])。除T分期外,其他重要的预后因素还有N分期(N0期与N1-3期:3年无复发生存率分别为68%和37.2%,p<0.001)和组织病理学分级(G1级与G3/4级:3年无复发生存率分别为74%和37.1%,p<0.01)。122例(43.1%)患者出现复发,其中75.4%为局部复发,12.3%为局部区域复发,8.2%为远处转移,4.1%为合并复发。50例复发患者接受了挽救性治疗。其中17例患者达到完全缓解。
即使对于本文所述的年龄中位数高且合并多种疾病的阴性选择患者群体,尤其是在早期阶段,根治性放疗也能取得良好的局部控制率。在更晚期阶段,即使是老年患者,也应采用手术与放疗相结合的治疗方法。